πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 64 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12378248

A1 adenosine receptor agonists and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12325708

Adenosine 2 receptor antagonists

Nektar Therapeutics Β· Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12310965

Treatment of cancer utilizing an identified adenosine fingerprint

Arcus Biosciences, Inc. Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12213990

A3 adenosine receptor ligand for use for achieving a fat loss effect

CAN-FITE BIOPHARMA LTD. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12174192

Methods for detecting and treating cancers having adenosine pathway activation

Corvus Pharmaceuticals, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12168023

Inhibitors of adenosine 5β€²-nucleotidase

Arcus Biosciences, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116635

Methods for detecting and treating cancers having adenosine pathway activation

Corvus Pharmaceuticals, Inc. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11795443

Uses of adenosine base editors

Beam Therapeutics Inc. Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11591579

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11584923

Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

HALOZYME, INC. Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11471528

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The Government of the United States of America as represented by the Secretary of the Department Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11396647

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System Β· Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254686

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

Corvus Pharmaceuticals, Inc. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11246871

Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

Northwestern University Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11155803

Adenosine deaminase base editors and methods of using same to modify a nucleobase in a tar

Beam Therapeutics Inc. Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11118167

Enzyme-mediated depletion of adenosine and/or methylthioadenosine

The Board of Regents of the University of Texas System Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11058704

Inhibitors of adenosine 5β€²-nucleotidase

Arcus Biosciences, Inc. Β· Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11040091

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods fo

The Regents of the University of California Β· Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10583180

Method for treating adenosine deaminase severe combined imunodeficiency

The Regents of the University of California Β· Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10577368

A3 adenosine receptor agonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376515

Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activati

Northwestern University Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10314908

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The United States of America as represented by the Secretary of the Department of Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10265337

Use of A3 adenosine receptor agonist in osteoarthritis treatment

CAN-FITE BIOPHARMA LTD. Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10016432

Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted